Safety, tolerability, pharmacokinetics, and pharmacodynamics of the afucosylated, humanized anti-EPHA2 antibody DS-8895a: a first-in-human phase I dose escalation and dose expansion study in patients with advanced solid tumors

BACKGROUND: Erythropoietin-producing hepatocellular receptor A2 (EPHA2) is overexpressed on the cell surface in many cancers and predicts poor prognosis. DS-8895a is a humanized anti-EPHA2 IgG1 monoclonal antibody afucosylated to enhance antibody-dependent cellular cytotoxicity activity. We conducte...

Descripción completa

Detalles Bibliográficos
Autores principales: Shitara, Kohei, Satoh, Taroh, Iwasa, Satoru, Yamaguchi, Kensei, Muro, Kei, Komatsu, Yoshito, Nishina, Tomohiro, Esaki, Taito, Hasegawa, Jun, Kakurai, Yasuyuki, Kamiyama, Emi, Nakata, Tomoko, Nakamura, Kota, Sakaki, Hayato, Hyodo, Ichinosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694490/
https://www.ncbi.nlm.nih.gov/pubmed/31412935
http://dx.doi.org/10.1186/s40425-019-0679-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694490/
https://www.ncbi.nlm.nih.gov/pubmed/31412935
http://dx.doi.org/10.1186/s40425-019-0679-9

Ejemplares similares